A PILOT STUDY OF COMBINATIONS OF EXCIPIENTS IN THE TECHNOLOGY OF RECTAL SUSPENSION WITH GRANULES CONTAINING 5-AMINOSALICYLIC ACID AND FOLIC ACID
The anti-inflammatory drug mesalazine is a leading pathogenetic agent for the conservative treatment of mild and moderate forms of inflammatory bowel diseases. With mesalazine therapy, remission is formed in 60-70% of patients with Crohn's disease. The use of 5-aminosalicylic acid derivatives reduces folate absorption and may lead to folic acid deficiency. The insufficient effectiveness of basic antiinflammatory therapy determines the relevance of the search for new drugs.The aim of the research was to develop the composition of a rectal suspension with two types of granules containing 5- aminosalicylic acid and folic acid.Material and methods. For the selection of excipients, we studied 18 different combinations of 5-aminosalicylic acid and folic acid with auxiliary substances. The method of wet granulation was used. The obtained granules were evaluated for their organoleptic properties, size, and disintegration.Results. During the experiment, the compositions of granules with 5-aminosalicylic and folic acids were optimized, an intestinalsoluble coating for granules was selected, and a dispersed medium for rectal suspension was selected.